Last reviewed · How we verify
Multivalent Pneumococcal Vaccine - Formulation 2 (multivalent-pneumococcal-vaccine-formulation-2)
At a glance
| Generic name | multivalent-pneumococcal-vaccine-formulation-2 |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Vaccine |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults (PHASE1, PHASE2)
- Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: